Table 1 Patient characteristics at baseline
Characteristic | n (%) |
|---|---|
Sex | |
Female | 18 (90) |
Male | 2 (10) |
Age: median (min; max) | |
Age at baseline (years) | 51.5 (40.0; 66.0) |
ECOG PS | |
0 | 6 (30) |
1 | 9 (45) |
2 | 5 (25) |
Primary tumor location | |
Breast | 12 (60) |
HER2 | 2 (10) |
Luminal | 4 (20) |
Triple-negative | 6 (30) |
Lung | 6 (30) |
Ovary | 1 (5) |
Melanoma | 1 (5) |
LMD type | |
Type I | 9 (45) |
Type II | 11 (55) |
Status of LMD | |
Progressing after local therapy | 0 (0) |
Untreated | 20 (100) |
Advanced disease at diagnosis | |
Yes | 14 (70) |
No | 6 (30) |
Visceral disease | |
Yes | 12 (60) |
No | 7 (35) |
No lesions at baseline | 1 (5) |
Brain-only disease | |
Yes | 6 (30) |
No | 13 (65) |
No lesions at baseline | 1 (5) |
Bone or liver metastases | |
Yes | 10 (50) |
Bone metastases | 6 (30) |
Liver metastases | 9 (45) |
No | 10 (50) |
Neurological symptoms at baseline | |
Yes | 12 (60) |
No | 8 (40) |
Previous ADCs | |
Yes | 7 (35) |
Trastuzumab deruxtecan | 1 (5) |
Sacituzumab govitecan | 5 (25) |
Mivertuximab soravtansine | 1 (5) |
No | 13 (65) |
Previous tucatinib | |
Yes | 0 (0) |
No | 20 (100) |
Previous chemotherapy + immunotherapy | |
Yes | 4 (20) |
No | 16 (80) |
Previous TKIs | |
Yes | 4 (20) |
Osimertinib | 3 (15) |
Tepotinib | 1 (5) |
Crizotinib | 1 (5) |
Sotorasib | 1(5) |
No | 16 (80) |
Previous treatment lines in advanced disease: median (min; max) | 2 (0; 6) |
